Shopping Cart
Remove All
Your shopping cart is currently empty
Neuropeptide W-23(human)
Copy Product Info
😃Good
Catalog No. TP1073Cas No. 383415-79-0
Alias NPW-23
Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.
Neuropeptide W-23(human)
Copy Product Info😃Good
Purity: 98.5%
Catalog No. TP1073Alias NPW-23Cas No. 383415-79-0
Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $123 | In Stock | In Stock | |
| 2 mg | $196 | In Stock | In Stock | |
| 5 mg | $372 | In Stock | In Stock | |
| 10 mg | $538 | In Stock | In Stock | |
| 25 mg | $855 | In Stock | In Stock | |
| 50 mg | $1,150 | In Stock | In Stock | |
| 100 mg | $1,550 | In Stock | In Stock | |
| 500 mg | $2,970 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.5%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2. |
| In vitro | NPW-23 increases the ICa,L in transfected human embryonic kidney 293 cells and VSMCs via GPR7 which may involve in the development of vascular hypertension. NPW-23 increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC[1]. |
| In vivo | NPW-23 increases pressure-induced vasotone of the rat mesenteric arteries. Importantly, the expression of NPW is decreased in the hypertensive rats[1]. NPW-23 (0.3 nmol, 1.0 nmol, and 3.0 nmol) induces significant increases in mean arterial pressure (MAP) in conscious, freely moving male rats. Rats that receive either 1.0 or 3.0 nmol NPW-23 demonstrate a significant increase in total activity, ambulatory activity, and duration of stereotypy. NPW-23 fails to elevate MAP in rats pretreated with phentolamine. NPW-23-induced increases in total activity, ambulatory activity, and duration of stereotypy are reduced significantly by pretreatment with the orexin type 1 receptor (OX1R) antagonist, SB-408124 which suggests that orexin neurons are downstream targets of NPW [2]. |
| Synonyms | NPW-23 |
| Molecular Weight | 2584.01 |
| Formula | C119H183N35O28S |
| Cas No. | 383415-79-0 |
| Smiles | C([C@@H](C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@H](C(N[C@@H](CC2=CN=CN2)C(N[C@H](C(N[C@H](C(N[C@H](C(=O)N3[C@H](C(N[C@H](C(N[C@@H](CC4=CC=C(O)C=C4)C(N[C@@H](CC5=CN=CN5)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@@H](CC(C)C)C(O)=O)=O)=O)CCSC)=O)CC(C)C)=O)CC(C)C)=O)=O)C)=O)C)=O)CCCNC(=N)N)=O)=O)[C@@H](C)C)=O)[C@@H](C)O)=O)=O)=O)CCCNC(=N)N)=O)CCC3)CO)=O)C)=O)[C@H](C)C)=O)=O)CCCCN)=O)=O)N)C=6C=7C(NC6)=CC=CC7 |
| Relative Density. | no data available |
| Sequence | Trp-Tyr-Lys-His-Val-Ala-Ser-Pro-Arg-Tyr-His-Thr-Val-Gly-Arg-Ala-Ala-Gly-Leu-Met-Gly-Leu |
| Sequence Short | WYKHVASPRYHTVGRAAGLMGL |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O: Soluble |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Neuropeptide W-23(human) | purchase Neuropeptide W-23(human) | Neuropeptide W-23(human) cost | order Neuropeptide W-23(human) | Neuropeptide W-23(human) chemical structure | Neuropeptide W-23(human) in vivo | Neuropeptide W-23(human) in vitro | Neuropeptide W-23(human) formula | Neuropeptide W-23(human) molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.